Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with myeloid blast phase chronic myeloid leukemia
Subjects who are either resistant or intolerant of imatinib mesylate
You may not be if
Subjects who are eligible and willing to undergo transplantation
Serious uncontrolled medical disorder or active infection
Uncontrolled or significant heart problems, such as congestive heart failure, recent heart attack, etc
Subjects receiving medications that may affect heart rhythm
Other malignancy/cancer other than CML
History of significant bleeding disorder unrelated to CML
Pregnant or breastfeeding women (subjects must avoid becoming pregnant)
Subjects received imatinib within 7 days, interferon or cytarabine within 14 days, a targeted anticancer medication within 14 days, an antineoplastic agent (other than hydroxyurea or anagrelide) within 28 days, or any other investigation medication in 28 days
Subject is receiving medications that affect platelet function or an anticoagulant
